CD47-SIRPα Immune Checkpoint Therapy

CD47-SIRPα Immune Checkpoint Therapy

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">CD47-SIRPα Immune Checkpoint Therapy</th>
</tr>
<tr>
<td class="label">Combination</td>
<td>Rationale</td>
</tr>
<tr>
<td class="label">NLRP3 inhibitor + Anti-CD47</td>
<td>Reduce inflammation (NLRP3) + enhance clearance (CD47)</td>
</tr>
<tr>
<td class="label">TREM2 agonist + Anti-CD47</td>
<td>Activate phagocytosis via two complementary pathways</td>
</tr>
<tr>
<td class="label">Anti-CD47 + ASO therapy</td>
<td>Enhance aggregate clearance while reducing production</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Company</td>
</tr>
<tr>
<td class="label">Magrolimab</td>
<td>Gilead</td>
</tr>
<tr>
<td class="label">Lemzoparlimab</td>
<td>I-Mab</td>
</tr>
<tr>
<td class="label">SRF231</td>
<td>Surface Oncology</td>
</tr>
<tr>
<td class="label">AO-176</td>
<td>Arch Oncology</td>
</tr>
<tr>
<td class="label">Challenge</td>
<td>Mitigation Approach</td>
</tr>
<tr>
<td class="label">Anemia</td>
<td>Fc-silent antibodies, intermittent dosing</td>
</tr>
<tr>
<td class="label">BBB penetration</td>
<td>Brain-penetrant small molecules, bispecific antibodies</td>
</tr>
<tr>
<td class="label">Off-target effects</td>
<td>Microglia-specific targeting (SIRPα-directed)</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Mechanism</td>
</tr>
<tr>
<td

CD47-SIRPα Immune Checkpoint Therapy

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">CD47-SIRPα Immune Checkpoint Therapy</th>
</tr>
<tr>
<td class="label">Combination</td>
<td>Rationale</td>
</tr>
<tr>
<td class="label">NLRP3 inhibitor + Anti-CD47</td>
<td>Reduce inflammation (NLRP3) + enhance clearance (CD47)</td>
</tr>
<tr>
<td class="label">TREM2 agonist + Anti-CD47</td>
<td>Activate phagocytosis via two complementary pathways</td>
</tr>
<tr>
<td class="label">Anti-CD47 + ASO therapy</td>
<td>Enhance aggregate clearance while reducing production</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Company</td>
</tr>
<tr>
<td class="label">Magrolimab</td>
<td>Gilead</td>
</tr>
<tr>
<td class="label">Lemzoparlimab</td>
<td>I-Mab</td>
</tr>
<tr>
<td class="label">SRF231</td>
<td>Surface Oncology</td>
</tr>
<tr>
<td class="label">AO-176</td>
<td>Arch Oncology</td>
</tr>
<tr>
<td class="label">Challenge</td>
<td>Mitigation Approach</td>
</tr>
<tr>
<td class="label">Anemia</td>
<td>Fc-silent antibodies, intermittent dosing</td>
</tr>
<tr>
<td class="label">BBB penetration</td>
<td>Brain-penetrant small molecules, bispecific antibodies</td>
</tr>
<tr>
<td class="label">Off-target effects</td>
<td>Microglia-specific targeting (SIRPα-directed)</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Anti-CD47/SIRPα</td>
<td>Enhance phagocytosis</td>
</tr>
<tr>
<td class="label">NLRP3 inhibitors</td>
<td>Reduce inflammation</td>
</tr>
<tr>
<td class="label">TREM2 agonists</td>
<td>Activate phagocytosis</td>
</tr>
<tr>
<td class="label">Anti-Aβ antibodies</td>
<td>Passive immunization</td>
</tr>
</table>

CD47-SIRPα immune checkpoint therapy represents a novel immunomodulatory strategy for neurodegenerative diseases that works by blocking the "don't eat me" signal that prevents microglia from clearing pathological protein aggregates. This approach has emerged from oncology where anti-CD47 antibodies have shown promise in enhancing immune-mediated tumor clearance, and is now being actively investigated for potential repurposing in Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and other proteinopathies.[@checkpoint2023]

The therapy targets the CD47-SIRPα signaling axis, a innate immune checkpoint that normally prevents phagocytosis of healthy cells but is co-opted by pathological protein aggregates to evade microglial clearance. By blocking this interaction, anti-CD47 therapies can restore the phagocytic capacity of microglia and enhance clearance of [amyloid-beta](/proteins/amyloid-beta) plaques, [tau](/proteins/tau) tangles, [alpha-synuclein](/proteins/alpha-synuclein) aggregates, and [TDP-43](/mechanisms/tdp-43-proteinopathy) proteinopathy.[@microglial2022]

Mechanism of Action

The "Don't Eat Me" Signal

CD47 is a transmembrane protein expressed on virtually all cells that functions as a self-recognition molecule. When CD47 binds to SIRPα (Signal Regulatory Protein alpha) on phagocytic cells including microglia, it sends an inhibitory signal that prevents engulfment. This mechanism is essential for preventing autoimmune attack on healthy tissues.[@sirpcd2023]

Pathological protein aggregates in neurodegenerative diseases—including amyloid-beta plaques, neurofibrillary tau tangles, Lewy bodies (alpha-synuclein), and TDP-43 inclusions—upregulate CD47 expression on their surface, effectively "hijacking" this protective mechanism to evade microglial phagocytosis. This represents a fundamental immune evasion strategy that sustains proteinopathy accumulation.[@pathological2023]

Antibody-Mediated Blockade

Anti-CD47 antibodies bind to CD47 on the surface of pathological aggregates, sterically preventing CD47 from engaging with SIRPα on microglia. This blockade restores phagocytic activity. Several antibody formats are being developed:

• Full-length monoclonal antibodies (e.g., magrolimab, lemzoparlimab): Fc-mediated effects
• Engineered fragments (e.g., single-chain variable fragments): Smaller molecular weight
• Brain-penetrant derivatives: Designed to cross the [blood-brain barrier](/entities/blood-brain-barrier)

Enhancement of Microglial Phagocytosis

Upon CD47-SIRPα blockade, microglia transition toward a more phagocytic phenotype. Research has demonstrated that:

Biological Rationale

Microglial Dysfunction in Neurodegeneration

Microglia, the resident immune cells of the CNS, play a dual role in neurodegeneration. In their surveilling state, they maintain CNS homeostasis. However, in disease states, they become dysfunctional:

• Impaired phagocytosis: Despite being present around amyloid plaques, microglia often fail to efficiently clear aggregates
• Chronic inflammation: [NLRP3 inflammasome](/entities/nlrp3-inflammasome) activation leads to IL-1β and IL-18 release, driving neuroinflammation
• TREM2 dependency: Phagocytic capacity is TREM2-dependent; TREM2 variants increase AD risk

Synergy with Other Immunomodulatory Approaches

CD47-SIRPα blockade can be combined with other immunomodulatory strategies:

This combination rationale is detailed in the Innate Immune Reprogramming page.[@innate]

Preclinical Evidence

Alzheimer's Disease Models

Multiple studies have demonstrated efficacy of CD47 blockade in AD models:

• 5xFAD mice: Anti-CD47 treatment reduced amyloid plaque burden by 40-60% with enhanced microglial recruitment[@anticd2022]
• [APP](/entities/app-protein)/PS1 mice: Improved cognitive performance alongside reduced plaque load
• Tau transgenic models: Reduced tau pathology and improved neuronal survival

Parkinson's Disease Models

• α-Synuclein transgenic mice: Anti-CD47 enhanced clearance of α-synuclein aggregates
• MPTP toxin model: Reduced dopaminergic neuron loss
• Lewy body dementia models: Improved pathology markers

ALS Models

• SOD1 transgenic mice: Enhanced clearance of mutant SOD1 aggregates
• TDP-43 models: Potential for TDP-43 proteinopathy clearance

Clinical Trial Status

Oncology Trials (Reference for Safety)

Anti-CD47 antibodies have undergone extensive clinical testing in oncology, providing safety data:

Key safety findings from oncology trials:[@magrolimab2023]

• Anemia: CD47 is expressed on red blood cells; hemolysis observed
• Infusion reactions: Manageable with premedication
• Off-tumor toxicity: On-target effects on normal cells

Neurodegeneration Trials

Currently, no anti-CD47 therapies have reached clinical trials for AD/PD/ALS. However:

• Brain-penetrant anti-CD47: Preclinical development ongoing
• Microglia-specific approaches: Targeting SIRPα on microglia rather than CD47 globally
• Combination approaches: NLRP3 inhibitors + anti-CD47 in development

Safety Considerations

Challenges for Neurodegeneration Applications

• Anemia due to phagocytosis of CD47-low erythrocytes
• Thrombocytopenia risk

• Requires brain-penetrant design or direct CNS delivery
• Intrathecal administration being explored

• Autoimmunity risk
• Infection susceptibility

Mitigation Strategies

Comparison to Other Immunomodulatory Approaches

Cross-Links to Related Pages

Gene and Protein Pages

• [CD47 Gene](/genes/cd47) - Gene encoding CD47 protein
• [CD47 Protein](/proteins/cd47-protein) - Full protein information
• [SIRPA Gene](/genes/sirpa) - Gene encoding SIRPα
• [SIRPA Protein](/proteins/sirpa-protein) - Full protein information
• [TREM2](/proteins/trem2) - Triggering receptor on myeloid cells 2

Cell Type Pages

• [Microglia](/cell-types/microglia-neuroinflammation) - CNS resident macrophages

Mechanism Pages

• [Neuroinflammation](/mechanisms/neuroinflammation) - Chronic neuroinflammation in neurodegeneration
• [Microglial Phagocytosis](/mechanisms/microglial-phagocytosis) - Mechanisms of microglial clearance
• [Innate Immune Reprogramming](/therapeutics/innate-immune-reprogramming-nlrp3-cd47) - Combination approach with NLRP3 inhibition

Disease Pages

• [Alzheimer's Disease](/diseases/alzheimers-disease) - Primary indication
• [Parkinson's Disease](/diseases/parkinsons-disease) - Alpha-synuclein clearance
• [Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis) - TDP-43 clearance
• [Frontotemporal Dementia](/diseases/frontotemporal-dementia) - TDP-43 proteinopathy

Treatment Pages

• [Novel Therapy Index](/novel-therapy-index) - Ranking of therapeutic concepts
• [Anti-Inflammatory Neuroprotection](/therapeutics/anti-inflammatory-neuroprotection) - Related immunomodulatory approaches

Future Directions

Near-Term (1-3 years)

• Development of brain-penetrant anti-CD47 antibodies
• Preclinical validation in non-human primates
• IND-enabling studies for first neurodegenerative indication

Medium-Term (3-5 years)

• Phase 1 clinical trials in AD/PD
• Biomarker development for patient selection
• Combination therapy trials with NLRP3 inhibitors

Long-Term (5-10 years)

• Personalized approaches based on genetic risk (TREM2 variants)
• Gene therapy approaches for sustained expression
• Prevention trials in pre-symptomatic individuals

Conclusion

CD47-SIRPα immune checkpoint therapy represents a promising new approach to neurodegenerative disease treatment by addressing the fundamental problem of impaired microglial phagocytosis. While significant challenges remain—particularly regarding safety and brain penetration—the strong preclinical data and existing clinical experience from oncology provide a foundation for translational development. The potential to directly enhance clearance of pathological proteins offers a disease-modifying mechanism distinct from existing approaches.

See Also

• [CD47 Gene](/genes/cd47)
• [CD47 Protein](/proteins/cd47-protein)
• [SIRPA Gene](/genes/sirpa)
• [SIRPA Protein](/proteins/sirpa-protein)
• [Neuroinflammation](/mechanisms/neuroinflammation)
• [Microglial Phagocytosis](/mechanisms/microglial-phagocytosis)
• [Innate Immune Reprogramming](/therapeutics/innate-immune-reprogramming-nlrp3-cd47)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [Bacterial Enzyme-Mediated Dopamine Precursor Synthesis](/hypothesis/h-7bb47d7a) — <span style="color:#ffd54f;font-weight:600">0.44</span> · Target: TH, AADC
• [TREM2-mediated microglial tau clearance enhancement](/hypothesis/h-b234254c) — <span style="color:#ffd54f;font-weight:600">0.55</span> · Target: TREM2
• [Enteric Nervous System Prion-Like Propagation Blockade](/hypothesis/h-2e7eb2ea) — <span style="color:#ffd54f;font-weight:600">0.55</span> · Target: TLR4, SNCA
• [Microbial Inflammasome Priming Prevention](/hypothesis/h-e7e1f943) — <span style="color:#81c784;font-weight:600">0.76</span> · Target: NLRP3, CASP1, IL1B, PYCARD
• [TREM2 Conformational Stabilizers for Synaptic Discrimination](/hypothesis/h-044ee057) — <span style="color:#ffd54f;font-weight:600">0.58</span> · Target: TREM2
• [CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: CYP46A1
• [Gamma entrainment therapy to restore hippocampal-cortical synchrony](/hypothesis/h-bdbd2120) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: SST
• [Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: SMPD1

Related Analyses:

• [Synaptic pruning by microglia in early AD](/analysis/SDA-2026-04-01-gap-v2-691b42f1) &#x1f504;
• [Lipid raft composition changes in synaptic neurodegeneration](/analysis/SDA-2026-04-01-gap-lipid-rafts-2026-04-01) &#x1f504;
• [TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) &#x1f504;
• [Epigenetic clocks and biological aging in neurodegeneration](/analysis/SDA-2026-04-01-gap-v2-bc5f270e) &#x1f504;
• [Autophagy-lysosome pathway convergence across neurodegenerative diseases](/analysis/SDA-2026-04-01-gap-011) &#x1f504;